What We Fund

Gilead is inspired by the work that our grantees do to improve access and eliminate barriers to healthcare, advance education among patients and healthcare professionals, and help build strong local communities. Gilead supports projects across multiple therapeutic areas — HIV/AIDS and liver diseases.

This specific website is designed to highlight potential giving efforts in China and to provide China based non-profit organizations implementing projects/programs in country, steps on how to apply for grant funding.


Continual advances in medical research means millions of people with HIV are living longer, more fulfilling lives today. However, HIV continues to have a devastating impact, especially on people who belong to underserved communities and those lacking access to medical care. Gilead supports organizations working to help individuals learn their status and get the care they need. We also support organizations looking to solve the challenges of tomorrow, including:

  • Screening and linkage to care programs
  • Reducing stigma associated with HIV
  • Providing education on latest standard of care for managing HIV
  • Programs focused on at risk groups such as young adults
  • Education on HIV transmission

Hepatitis C

Hepatitis C now represents a global viral pandemic and is the fourth most commonly reported infectious disease in China. Yet, public awareness of this disease remains limited because of its disproportionate impact on drug users, ethnic minorities and other at-risk groups. Gilead is working to change this by funding organizations that raise awareness of the importance of testing and access to care among these groups, as well as those that:

  • Look for ways to increase capacity among providers
  • Raise disease awareness
  • Screen and link to care
  • Eliminate intrinsic barriers to care and treatment to decrease social stigma
  • Deliver programs focused on marginalized groups, such as injection drug users

Hepatitis B

China’s hepatitis B burden continues to be a significant public health concern. It is estimated that between now and 2030, more than 10 million people could potentially succumb to chronic hepatitis-related cirrhosis and liver cancer – most of them due to hepatitis B. Although large-scale immunization programs have decreased chronic hepatitis B infection among children, further multi-faceted efforts focused on the following need to be implemented across all regions:

  • Mother to child transmission
  • Stigma and discrimination associated with living with hepatitis B
  • Testing and screening especially for those in rural communities and across socioeconomic strata
  • Education around medication adherence programs and their importance